Aminoglycosides Global Market Report 2024

The global aminoglycosides market has grown strongly in recent years. It will grow from $1.77 billion in 2023 to $1.86 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The expansion observed during the historical period can be attributed to key factors such as the discovery and development of antibiotics, advancements in medicinal chemistry, the clinical effectiveness of these antibiotics in treating gram-negative infections, their broad-spectrum antibacterial activity, initiatives for hospital-acquired infection control, global population growth, prevention of post-surgery infections, and significant investments in research and development.

The global aminoglycosides market is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The anticipated growth in the forecast period can be attributed to several factors, including advancements in antibiotic stewardship practices, the implementation of personalized medicine approaches, innovations in drug delivery methods, the global spread of antibiotic-resistant strains, a heightened focus on addressing rare diseases, expanding applications in dermatology, and increased efforts in patient education regarding antibiotic use. Major trends expected during the forecast period encompass biotechnological innovations, the rise of combination therapies, technological advancements in production processes, and intensified price competition within the market.

The aminoglycosides market is anticipated to witness growth due to the escalating incidences of animal disease outbreaks. These outbreaks significantly impact the normal functions of animals and create a demand for aminoglycosides, like amikacin and gentamicin, widely used in veterinary medicine. A recent example is the anthrax outbreak reported and monitored in remote areas of Canada's Wood Buffalo National Park in July 2022. This trend is expected to continue, further boosting the demand for aminoglycosides within the market.

The growing ownership of pets is poised to fuel the expansion of the aminoglycosides market. The increased number of pet owners, who are responsible for the care and well-being of animals kept as companions, contributes to the market's growth by expanding the customer base. This surge in pet ownership encourages preventive healthcare practices for pets and drives investments in veterinary pharmaceuticals, including aminoglycosides, to address various health needs. An example of this growth is evident in the UK, where approximately 57% of households, totaling 16.2 million, have 38 million pets, as reported by Improve International in March 2023. This rise in pet ownership remains a driving force behind the growth of the aminoglycosides market.

Process innovation emerges as a significant trend in the aminoglycosides market. Key companies within this sector are focused on developing novel process solutions to fortify their market positions. As an illustration, in September 2021, CPC Biotech introduced Aminosniper, an enzyme-based product designed for the inactivation of aminoglycosidic antibiotics. Aminosniper serves as a lab reagent for verifying the sterility of products or surfaces contaminated by antibiotics from the aminoglycosides class. This strategic innovation reflects the industry's commitment to advancing process solutions, contributing to the market's growth and technological advancements.

Major companies within the aminoglycosides market are introducing innovative products like the Aminosniper inactivator to enhance their market competitiveness and profitability. This inactivator, a broad-spectrum solution designed to neutralize aminoglycoside antibiotics, serves as an essential tool in rendering antibiotics such as ribostamycin, gentamicin, tobramycin, and neomycin inactive. In September 2021, Cpc Biotech S.R.L., an Italy-based biotechnology company, unveiled the Freeze-dried Aminosniper, available in a freeze-dried format. This product finds applications in various areas, including media fill, total count, aminoglycoside sterility testing, and assessing the susceptibility of novel aminoglycoside antibiotics to inactivation by aminoglycosidases.

In April 2022, Animal Dermatology Group Inc., a US-based veterinary company, executed the acquisition of Austin Veterinary Dermatology & Allergy. The strategic acquisition, completed for an undisclosed amount, is part of Animal Dermatology Group's ongoing efforts to expand its geographic presence and consolidate its market position. Through this acquisition, the company aims to broaden its scope and offer top-tier treatment for skin diseases across more regions. This move reinforces Animal Dermatology Group's commitment to enhancing its expertise in veterinary dermatology. Austin Veterinary Dermatology & Allergy, a US-based biotechnology company, aligns well with the expansion goals of Animal Dermatology Group.

Major companies operating in the aminoglycosides market report are Kremoint Pharma Pvt. Ltd., Vega Pharma Ltd., Jiangxi Bolai Pharmacy Co. Ltd., Xian Wison Biological Technology Co. Ltd., Hangzhou Uniwise International Co. Ltd., HuvePharma Inc., Yi Chang Veterinary Medicine Factory, Medson Pharmaceuticals, Medico Remedies Pvt. Ltd., Cipla Limited, Pfizer Inc., Allergan PLC, Teva Pharmaceutical Industries Ltd., Zoetis Inc., Taiwan Fructose Sdn. Bhd., Novartis AG, Johnson & Johnson Inc., Bristol Myers Squibb Company, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Lifescience limited, Lupin Limited, Aurobindo Pharma Limited, Fresenius Kabi AG, Aspen Pharmacare Holdings Limited, Mylan N.V., Sanofi SA, Wyeth Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., GlaxoSmithKline plc

Asia-Pacific was the largest region in the aminoglycosides market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the aminoglycosides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aminoglycosides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Among the primary products in the aminoglycoside category are neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, kanamycin, and others. Neomycin, for instance, is specifically employed to prevent bacterial infections in the intestines. Derived from the metabolic products of Streptomyces fradiae, neomycin is recognized as a broad-spectrum aminoglycoside antibiotic. Aminoglycosides are administered through various routes, including injectables (parenteral), feed, intra-mammary, topical, and oral applications. Their use extends across veterinary medicine, addressing conditions such as skin infections, respiratory diseases, urinary tract infections, pelvic diseases, and various other ailments.

This report provides aminoglycosides market statistics, including aminoglycosides industry global market size, regional shares, competitors with an aminoglycosides market share, detailed aminoglycosides market segments, market trends and opportunities, and any further data you may need to thrive in the aminoglycosides industry. This aminoglycosides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aminoglycosides market consists of sales of plazomicin and netilmicin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.